Biological marker(s) for the clinical diagnosis of Alzheimer's disease Hiroyuki ARAI 1 , Takuma NAKAGAWA 1 , Yoichi KOSAKA 1 , Makoto HIGUCHI 1 , Toshifumi MATSUI 1 , Nobuyuki OKAMURA 1 , Manabu TASHIRO 1 , Masanori TERAJIMA 1 , Shigeru ITABASHI 1 , Yuichi MORIKAWA 1 , Hidetada SASAKI 1 , Susumu HIGUCHI 2 , Taro MURAMATSU 2 , Sachio MATSUSHITA 2 1Department of Geriatric Medicine, Tohoku University School of Medicine 2Department of Psychiatry, National Institute or Alcoholism, Kurihama National Hospital Keyword: アルツハイマー病 , 脳脊髄液タウ蛋白 , 瞳孔散大試験 , アポタンパクE遺伝子 , β-アミロイド蛋白 pp.130-139
Published Date 1997/2/10
DOI https://doi.org/10.11477/mf.1431901460
  • Abstract
  • Look Inside

There is a compelling need to develop diagnostic marker (s) to confirm a clinical diagnosis of Alzheimer's disease (AD) in order to unequivocally identify AD patients during life for emerging therapeutic interventions. Cerebrospinal fluid (CSF) tau (CSF-tau) appears to be a reliable marker to distinguish AD from non-AD patients with a sensitivity of 93.8% and a specificity of 75.0%. CSF-tau is elevated in AD irrespective of age at onset, clinical stage, apolipoprotein E genotype (ApoE), α1-antichymotrypsin genotype, presenilin-1 genotype, sex and racial group. In contrast, ApoE genotyping can not provide the presence or absence of AD nor should be used as a sole diagnostic test for AD. Biological marker (s) would be used not only for an aid in diagnosis, but also for monitoring of therapeutic response as well as for the early detection of AD patients.

Copyright © 1997, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1243 印刷版ISSN 0001-8724 医学書院